Pharmaceutical company Corcept Therapeutics has announced that its Korlym (mifepristone) 300 mg tablets are available to patients outside the U.S. through an Idis Access Program.
Through a regulatory-compliant and ethical channel on a named-patient basis, Idis Access Programs enable patients worldwide to be prescribed investigational or approved drugs prior to their commercial launch in the patient's country.
Since April 2012, Corcept has been offering Korlym in the U.S. as a once-daily oral treatment for hyperglycemia secondary to endogenous Cushing's syndrome in adult patients with type 2 diabetes or glucose intolerance who have failed surgery or are not candidates for surgery.
"We are pleased to partner with Idis so that physicians outside the United States can prescribe Korlym," said Corcept Vice President of Commercial Operations Steven Lo. "We are dedicated to meeting the needs of patients worldwide. Our partnership with Idis will help us make sure that every Cushing's syndrome patient who could benefit from Korlym will have access to the medicine."
Interested licensed healthcare professionals outside the U.S. who have patients that might benefit from Korlym can contact Idis directly for more information.
For more information, visit www.corcept.com
Please see disclaimer on the MissionIR website